Inc. reports on research into a fat-burning pathway that works differently from Ozempic, which acts on appetite.
Recap by typeshit. Full story at Inc.com.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
Revenue rose to $13.2M from $7.6M a year earlier while net loss widened to $61.9M, with the company also pointing to progress in its obesity pipeline.
The Nature Cardiovascular Research team found the protection held even when the peptides were given at reperfusion. So far the results come only from mice and cultured cells.
Loading…